ERN1 and plasma cell myeloma: For example, preclinical studies have demonstrated that the IRE1α RNase inhibitor MKC8866 has potent anti-tumor activity in various cancer types, including multiple myeloma, BCa, and PCa; in addition, it synergizes with anti-cancer drugs that are in the clinic, such as, enzalutamide, abiraterone, cabazitaxel, docetaxel, and paclitaxel [81, 83, 96].